Vera Therapeutics, Inc. $VERA Shares Bought by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG grew its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 87.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,317 shares of the company’s stock after acquiring an additional 25,750 shares during the quarter. J. Safra Sarasin Holding AG owned approximately 0.09% of Vera Therapeutics worth $1,608,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Vestal Point Capital LP increased its stake in Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Vera Therapeutics by 7.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,294,958 shares of the company’s stock valued at $30,513,000 after buying an additional 92,149 shares during the period. American Century Companies Inc. boosted its holdings in shares of Vera Therapeutics by 89.3% in the 2nd quarter. American Century Companies Inc. now owns 714,428 shares of the company’s stock valued at $16,832,000 after buying an additional 336,978 shares during the period. MPM Bioimpact LLC grew its position in shares of Vera Therapeutics by 35.4% during the 2nd quarter. MPM Bioimpact LLC now owns 563,075 shares of the company’s stock valued at $13,266,000 after buying an additional 147,356 shares during the last quarter. Finally, Capricorn Fund Managers Ltd acquired a new stake in Vera Therapeutics during the third quarter worth about $13,097,000. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Stock Down 3.5%

VERA opened at $45.11 on Thursday. The stock’s 50 day moving average price is $45.25 and its 200 day moving average price is $32.32. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. The stock has a market cap of $2.88 billion, a P/E ratio of -11.31 and a beta of 1.16. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same period in the prior year, the business posted ($0.85) earnings per share. As a group, research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VERA has been the subject of a number of research reports. Wedbush lifted their target price on Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, January 21st. Finally, TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vera Therapeutics has an average rating of “Moderate Buy” and an average price target of $74.83.

Insider Transactions at Vera Therapeutics

In related news, SVP Joseph R. Young sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the sale, the senior vice president owned 47,839 shares of the company’s stock, valued at $1,390,201.34. The trade was a 23.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Patrick G. Enright purchased 5,882 shares of the firm’s stock in a transaction on Thursday, December 11th. The shares were purchased at an average cost of $42.50 per share, with a total value of $249,985.00. Following the completion of the purchase, the director owned 5,882 shares in the company, valued at $249,985. This represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 16.30% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.